

Running Head: fMRI assessment of motor learning and escitalopram

Modulation of premotor cortex response to sequence motor learning during escitalopram-intake

Eóin N. Molloy^{1,2,3,4}, Karsten Mueller^{2,5}, Nathalie Beinhořlzl^{1,3}, Maria Blöchl^{2,3,8}, Fabian A. Piecha^{1,3}, André Pampel⁵, Christopher J. Steele^{3,12}, Ulrike Scharrer^{1,3}, Gergana Zheleva^{1,3}, Ralf Regenthal⁹, Bernhard Sehm^{3,7,13}, Vadim V. Nikulin^{3,6}, Harald E. Möllner^{2,5}, Arno Villringer^{2,3,4,10,11} & Julia Sacher^{1,2,3,10}

Emotion & Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences¹
International Max Planck Research School NeuroCom²
Dept. of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences³
Faculty of Medicine, Leipzig University⁴
Nuclear Magnetic Resonance Unit, Max Planck Institute for Human Cognitive and Brain Sciences⁵
Centre for Cognition and Decision Making, Institute for Cognitive Neuroscience, National Research University Higher School of Economics⁶
Neuroplasticity & Motor Recovery Group, Max Planck Institute for Human Cognitive and Brain Sciences⁷
Dept. of Psychology, University of Münster⁸
Division of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, Leipzig University⁹
Clinic for Cognitive Neurology¹⁰
Berlin School of Mind and Brain¹¹
Dept. of Psychology, Concordia University¹²
Dept. of Neurology, Martin Luther University Halle-Wittenberg¹³

Correspondence:

Eoin N. Molloy, MSc - Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1A, 04103, Leipzig, Germany, molloy@cbs.mpg.de, tel: +49 341 9940-2215

Julia Sacher, MD, PhD - Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1A, 04103, Leipzig, Germany, sacher@cbs.mpg.de, tel: +49 341 9940-2409

Running Title: fMRI assessment of motor learning and escitalopram

Figures: 4, Tables: 3

Supplementary Figures: 1, Supplementary Tables: 4

Word Count (including headings):

Abstract: 149

Introduction: 643

Materials and Methods: 1492

Results: 590

Discussion: 1382

Total

(Including

Abstract):

4256

Running Head: fMRI assessment of motor learning and escitalopram

Abstract:

The contribution of selective serotonin reuptake inhibitors (SSRIs) to motor learning by inducing motor cortical plasticity remains controversial given diverse findings from positive preclinical data to negative findings in recent clinical trials. To empirically address this translational disparity, we use functional magnetic resonance imaging (fMRI) in a double-blind, randomized controlled study to assess whether 20 mg escitalopram improves sequence-specific motor performance and modulates cortical motor response in 64 healthy female participants. We found decreased left premotor cortex responses during sequence-specific learning performance comparing single dose and steady escitalopram state. Escitalopram plasma-levels negatively correlated with the premotor cortex response. We did not find evidence in support of improved motor performance after a week of escitalopram-intake. These findings do not support the conclusion that 1-week escitalopram intake increases motor performance but could reflect early adaptive plasticity with improved neural processing underlying similar task performance when steady peripheral escitalopram levels are reached.

Key words: *selective serotonin reuptake inhibitors, sequential motor learning, neural plasticity, functional* *MRI.*

Running Head: fMRI assessment of motor learning and escitalopram

1 Introduction:

2 Motor learning is the improved performance of a motor task following practice¹ and is modulated
3 by monoaminergic transmission in cortical and subcortical motor networks^{2,3,4}. Research on this
4 monoaminergic basis of motor learning typically focuses on dopamine signaling in both health^{5,6}
5 and disease⁷. Evidence from rodents⁸ and stroke patients⁹, however, suggests that serotonin also
6 critically modulates motor behavior. Selective serotonin reuptake inhibitors (SSRIs), commonly
7 prescribed medications for depression and anxiety disorders¹⁰, increase extracellular serotonin
8 and successfully treat post-stroke depression¹¹. In the absence of depressive symptoms, several
9 studies have also demonstrated an effect of SSRIs on the recovery of post-stroke motor
10 dysfunction¹². Notably, the FLAME trial (Fluoxetine for Motor Recovery After Acute Ischemic
11 Stroke⁹) showed approximately 50% motor recovery in 57 patients following combined
12 fluoxetine treatment and physiotherapy, in a multi-center Randomized Controlled Trial (RCT).
13 These findings were further supported by a meta-analysis of 52 RCTs in 4,060 patients, which,
14 however, also acknowledged heterogeneity and methodological shortcomings in a substantial
15 proportion of trials¹³.

16

17 Possible mechanisms underlying SSRI modulation of motor performance and learning include
18 anti-inflammatory^{14,15} and neurotrophic effects¹⁶ such as increased neurogenesis¹⁷, proliferation¹⁸,
19 protein expression enhancement¹⁹, upregulation of beta1-adrenergic receptors²⁰, downregulation
20 of GABA-transmission^{21,22}, and hippocampal long-term potentiation²³. These findings suggest
21 that SSRIs may increase responsivity to environmental stimuli, possibly via changes in inhibitory
22 and excitatory balance²⁴ and reorganization of cortical networks²⁵⁻²⁷. Studies in humans have
23 provided support for this by demonstrating changes in resting state functional connectivity
24 induced by a single dose of escitalopram²⁸. Additionally, decreases in resting state alpha-
25 frequency band induced by tryptophan depletion²⁹, which are hypothesized to reflect alterations

Running Head: fMRI assessment of motor learning and escitalopram

26 in the excitatory and inhibitory balance of cortical networks, have been observed in healthy
27 volunteers. Moreover, preliminary functional magnetic resonance imaging (fMRI) evidence has
28 linked decreased functional responses in the motor network with improved motor performance
29 following fluoxetine administration³⁰⁻³³.

30

31 Recent large-scale RCTs in stroke patients such as the TALOS³⁴ and FOCUS trials³⁵, involving
32 over 642 and 3,000 patients, respectively, however, do not suggest beneficial effects of SSRIs on
33 functional recovery. Critically, however³⁶, these RCTs were conducted against the backdrop of
34 routinely available rehabilitation and did not combine SSRI administration with a clearly defined
35 motor learning paradigm, nor did they assess functional brain responses to SSRI intake. As a
36 result, no previous study, either in healthy participants or in patients, has successfully leveraged
37 prolonged training on an established motor learning paradigm in combination with SSRI-
38 administration and fMRI in an adequately powered sample. Therefore, the hypothesis of whether
39 SSRI administration, specifically in combination with an established motor learning paradigm,
40 induces a beneficial effect on motor learning performance and changes the cortical motor
41 response underlying the learning performance, remains to be tested empirically.

42

43 The current study utilizes fMRI to address whether one week of SSRI administration in
44 combination with a sequential motor learning task improves sequence specific motor
45 performance and elicits changes in concurrent cortical motor response during task performance.
46 In a double-blind, randomized controlled pharmacofMRI study, we administered 20 mg (to
47 reach 80% serotonin transporter (5-HTT) occupancy)³⁷ of escitalopram, the most 5-HTT selective
48 and rapid onset SSRI^{38,39} or placebo, to healthy females undergoing parallel fMRI assessment and
49 training on a variant of the sequential pinch force task (SPFT)⁴⁰. We chose a healthy
50 homogeneous and young sub-sample to avoid variance associated with pathology^{41,42}, sex³³, and

Running Head: fMRI assessment of motor learning and escitalopram

51 age⁴³. Our *a priori* hypotheses were (1) that one week of escitalopram intake would improve
52 sequential motor performance relative to placebo, as assessed by performance in a temporal lag
53 condition on the SPFT, calculated as the time difference between a computer controlled visual
54 stimulus and participant control of a pinch-force device. (2) By specifying this sequence-learning
55 condition in an fMRI contrast (hereafter referred to as the learning contrast, i.e., the difference of
56 functional brain responses between two experimental conditions comprising two levels of task
57 difficulty), we also hypothesized escitalopram-induced changes in fMRI-response in core
58 components of the motor network during task performance.

Running Head: fMRI assessment of motor learning and escitalopram

59 **Materials and methods:**

60 **Participants & eligibility:**

61 Eligible individuals were right-handed, aged 18–35 years, with a body mass index (BMI) 18.5-25
62 kg/m², without history of neurological or psychiatric illness, and female on oral contraceptives
63 for ≤ 3 months^{44,45} to eliminate sex and hormone-dependent escitalopram responsivity⁴⁶.
64 Exclusion criteria were medication use, contraindications for MRI, tobacco use, alcohol abuse,
65 positive drug or pregnancy tests, professional musicianship and athleticism, and abnormal QT
66 times in electrocardiogram screenings. In total, 88 participants were screened with 71 enrolled.
67 Analyses included 64 volunteers for the behavioral analysis as 6 (escitalopram=4) chose to
68 discontinue participation and n=1 (placebo) was excluded due to a pre-analytical error in plasma
69 sample acquisition. Sixty volunteers were included in functional imaging analysis as 4 were
70 excluded due to MRI data quality concerns (2 escitalopram) due to head movement. 1 volunteer
71 from the placebo group was excluded due to an artefact in an anatomical sequence and 1
72 participant from the escitalopram group was excluded due to an artefact detected during
73 acquisition of the functional sequence (Supplementary Figure 1).

74

75 **Study design and procedure:**

76 The Ethics committee of the Faculty of Medicine, Leipzig University approved all procedures
77 (approval number 390/16-ek) and the study was pre-registered at clinicaltrials.gov (ID:
78 NCT03162185). Participants were randomized to receive either 20 mg of escitalopram or placebo
79 (mannitol/aerosol) orally for 7 days. Randomization was performed by the Central Pharmacy of
80 Leipzig University with equal condition allocation. Sequential motor training was conducted 5
81 times (baseline, on day 1 of escitalopram administration, days 5 and 6 of drug administration, and
82 at steady state – after 7 days) (Figure 1). Functional magnetic resonance imaging data (fMRI) and
83 serum mature brain-derived neurotrophic factor (mBDNF) samples were acquired at baseline,

Running Head: fMRI assessment of motor learning and escitalopram

84 single dose, and steady state. Electrocardiogram recordings were conducted at single dose, day 4,
85 and steady state to monitor potential changes in QT intervals. Adverse reactions to escitalopram
86 were recorded using the antidepressant side-effects checklist (ASEC)⁴⁷. All participants remained
87 under medical supervision during the experiment. Concentrations of escitalopram in plasma was
88 assessed chromatographically using a quality control sample. Deviation of the measured
89 escitalopram concentration of the sample was tested for an acceptance interval of $\pm 15\%$. All
90 behavioral and fMRI assessments took place 3 hours after escitalopram or placebo intake to allow
91 for escitalopram to reach maximum levels in serum⁴⁸.

92 ***Figure 1***

93 **Sequential pinch force task:**

94 We assessed sequence motor learning using a variant of the sequential pinch force task (SPFT),
95 with Presentation (v16.5) running on WindowsXP. Baseline, single dose, and steady state
96 measurements took place during fMRI, while day 5 and day 6 were conducted outside the
97 scanner on an identical separate device. Task completion involved controlling the rise and fall of
98 a yellow bar (force) via the participant's thumb and index finger (attenuated to individual
99 strength) while attempting to match the speed of a moving computer controlled blue reference bar
100 (Figure 1). We measured performance in two conditions: (1) a control condition, where the
101 reference bar moves sinusoidally and (2) a sequence-specific learning condition, in which the
102 reference moves in a sequential pattern that remains stable across sessions. A rest condition
103 punctuated training to avoid fatigue. Each session consisted of 5 blocks with 3 trials per block
104 and cycled through simple, rest, and learning. Participants received no feedback regarding
105 performance. To assess performance, we calculated the time difference (lag) in milliseconds
106 between the reference and force bar during the learning trials.

Running Head: fMRI assessment of motor learning and escitalopram

107 **Demographic data and statistical analysis:**

108 Independent samples *t*-tests using the R statistical programming language⁴⁹ tested for potential
109 group differences in age, BMI, downregulated hormonal profile, and on total ASEC scores at
110 single dose and steady state. A power analysis conducted using G*Power⁵⁰ (v.3.1.9.4) assuming
111 statistical power of 95% to detect a significant effect of escitalopram on sequence motor learning
112 (*i.e. learning rate over 5 behavioral assessments compared to placebo*) with a small effect size
113 and an α -level of <0.05 suggested a minimum sample size of 56, with 28 participants per group.
114 To account for potential drop-outs, we aimed to include 60 participants in total.

115 **Behavioral data preprocessing:**

116 All SPFT data were preprocessed using in house Matlab scripts. Quality control used an outlier
117 labeling approach⁵¹ implemented in Python (v2.7.15) in which trial, condition, group, and
118 outcome specific interquartile ranges were multiplied by a factor of 1.5 to compute upper and
119 lower bound thresholds.

120 **Behavioral data analysis:**

121 All behavioral data analyses were conducted using R.

122 (1) Independent samples *t*-tests assessed baseline group differences using the ‘t.test’ function to
123 assess efficacy of randomization.

124 (2) Comparisons between groups over time employed an omnibus linear random-intercept mixed
125 effect modeling approach using the ‘lmer’ function, within the ‘lme4’ package in R (independent
126 factors: *group*, *time*, dependent variable: *lag*). Contributions of each fixed effects were assessed
127 with a likelihood ratio test for improvement of model fit.

Running Head: fMRI assessment of motor learning and escitalopram

128 (3) Post-hoc independent samples *t*-tests were conducted on mean single dose and steady state
129 scores to assess potential group differences at each critical time point of escitalopram-
130 administration. Additionally, the delta (difference between mean performance at steady state
131 compared to baseline) was compared between groups for each outcome via independent samples
132 *t*-tests. Bayes Factor *t*-tests using the ‘ttestBF’ function in the ‘BayesFactor’ package assessed the
133 likelihood of the null hypothesis for all independent sample analyses.

134 (4) Pearson’s correlation analyses assessed potential associations between total ASEC scores and
135 mean lag performance at both single dose and steady state.

136 **fMRI data acquisition:**

137 fMRI data were acquired with gradient-echo echo planar imaging (EPI) on a 3-Tesla
138 MAGNETOM Verio scanner (Siemens, Erlangen, Germany, 32-channel head-coil, flip angle 90°,
139 TR=2000 ms, TE=30 ms, field of view=192×192 mm², 30 slices, 64×64 matrix, 3×3×3mm³
140 nominal resolution, 495 volumes, aligned -15° along the anterior to posterior commissure, ~16
141 minutes). A whole-brain three dimensional T1-weighted Magnetization Prepared Rapid Gradient-
142 echo (MPRAGE) was also acquired at each time point for co-registration⁵² with inversion time,
143 TI=900 ms, TR=2300 ms, TE=2.98 ms, 1×1×1mm³ nominal isotropic resolution, ~9 minutes⁵³.

144 **fMRI data analysis – Preprocessing and first-level analysis:**

145 Data pre-processing was conducted using SPM12 (v12.7219). Data were realigned, unwarped,
146 normalized to Montréal Neurological Institute (MNI) space, and smoothed with a Gaussian
147 kernel (8mm at full-width-half-maximum). First level analysis was performed for baseline, single
148 dose and steady state separately using a general linear model (GLM) including all three
149 experimental conditions: learning, simple, and rest. In addition, each analysis contained head-
150 movement parameters obtained during preprocessing motion correction. Following parameter

Running Head: fMRI assessment of motor learning and escitalopram

151 estimation, we generated contrast images specific to sequence learning by specifying the learning
152 contrast (i.e., the difference between the learning and simple conditions).

153 **fMRI data analysis – Group-level analysis:**

154 Using contrast images obtained at the first level, second level analyses were performed with
155 SPM12 in Matlab (v9.7). Results were considered statistically significant at a cluster-defining
156 threshold of $p < 0.001$ corrected at $p < 0.05$ using family-wise error (FWE) for multiple
157 comparisons at the cluster-level.

158 (1) An independent-samples t -test assessed potential differences in the learning contrast between
159 groups at baseline.

160 (2) Following baseline comparisons, we assessed changes across time within the escitalopram
161 group. Using a paired t -test, we each compared baseline to single dose, baseline to steady state,
162 and single dose to steady state. Both directions of each t -statistic were assessed to test for both
163 increases and decreases in fMRI response during the learning contrast over time.

164 (3) To investigate group differences with respect to results obtained in analyses (2), we specified
165 a flexible factorial model using factors for *subject* (for repeated measurements), *time* and *group*.
166 Comparisons from (2) yielding a significant difference were repeated within this model to
167 validate results from paired t -tests. Within this model, we tested for an interaction between *group*
168 and *time*. Additionally, a sensitivity analysis repeated this interaction analysis with an additional
169 regressor. Two mean behavioral measures for each participant (one for each timepoint) were
170 entered as nuisance covariates in the GLM⁵⁴. For these behavioral measures, we used the
171 behavioral sequence-specific learning measure “lag learning-simple score” (LLSS), as calculated
172 for each participant by subtracting the mean simple condition scores from the mean learning
173 condition lag scores.

Running Head: fMRI assessment of motor learning and escitalopram

174 (4) To visualize mean signal for the learning contrast for each group at baseline, single dose, and
175 steady state, a series of one-sample *t*-tests was conducted on each group at each timepoint
176 separately.

177 (5) In order to test for a correlation between motor performance improvement and change in the
178 learning contrast within the escitalopram group, we used the LLSS as an effect of interest within
179 a second flexible factorial design⁵⁴. Here, the model was generated using the factors *subject*,
180 *group*, and *LLSS*.

181 (6) With the aim of testing for a correlation between escitalopram plasma and brain kinetics
182 during the learning contrast, escitalopram plasma levels were entered as an effect of interest
183 within a third flexible factorial design⁵⁴, within the escitalopram group, using the factors *subject*,
184 *group*, and *plasma escitalopram levels*.

185 **Analysis of serum mature BDNF levels:**

186 A one-way repeated measures ANOVA was implemented in R using the ‘Anova’ function to
187 assess changes in serum mBDNF levels across time. Paired samples *t*-tests in both the
188 escitalopram and placebo groups compared baseline to steady state within each group, separately.

Running Head: fMRI assessment of motor learning and escitalopram

189 **Results:**

190 **Demographics:**

191 No differences were observed between groups in any baseline screening measures. Escitalopram
192 levels were within the expected range⁴⁹ (Table 1).

193 ***Table 1***

194 **Sequence-specific motor learning:**

195 We did not find any significant differences between the escitalopram and placebo groups on
196 behavioral measures of sequence-specific motor learning:

197 (1) Group comparisons of mean performance at baseline did not show any significant group
198 differences in sequence-specific motor learning behavior ($t=-0.25, p=0.80$).

199 (2) For group comparisons over time, a mixed effects model including a fixed effect of *time* fit
200 the data significantly better than a random-intercept only model, reflecting a decrease in lag
201 scores (Table 2). The fixed effect of *group* and the interaction of *time* and *group* did not show a
202 significant improvement in fit, demonstrating that, while both groups improved in sequence-
203 specific motor performance over time, they did so comparably (Figure 2).

204 (3) Post-hoc two-sample *t*-tests did not show a significant group difference in mean performance
205 at either single dose or steady state. Comparisons of the delta scores from baseline to steady state
206 did not show any significant differences between groups. Bayes Factor analysis of group
207 comparisons at single dose and steady, as well as the delta, yields moderate evidence in support
208 of the null hypothesis (Table 2).

209 (4) Additionally, correlation analyses did not show an association between total ASEC scores
210 with mean behavioral lag scores at either single dose ($r=-0.03, p=0.8,$) or at steady state ($r=0.11$
211 $p=0.37$), respectively.

212 ***Figure 2***

213

214 ***Table 2***

215

Running Head: fMRI assessment of motor learning and escitalopram

216 **Functional MRI responses during sequence-specific motor learning:**

217 (1) We did not observe any group differences in the learning contrast fMRI responses at baseline.

218 (2) Within the escitalopram group, we found a significant decrease of the learning contrast in
219 bilateral motor regions (Figure 3, escitalopram panel, blue overlay) when comparing single dose
220 with steady state. We did not observe any significant increases in whole-brain fMRI signal for
221 this learning contrast.

222 (3) Comparisons of groups over time reveals decreases in the learning contrast in the left
223 premotor cortex of the escitalopram group between single dose and steady state that are not
224 observed in placebo (Figure 3, interaction panel, yellow overlay). A sensitivity analysis
225 controlling for intra-subject variance in task performance replicates this result, showing a
226 significant *group by time* interaction with a decrease in the learning contrast from single dose to
227 steady state in the escitalopram group in the left premotor cortex (Table 3).

228 (4) One-sample *t*-tests across the learning contrast images in each group at each time point show
229 bilateral activation in both the escitalopram and placebo groups at each of baseline, single dose,
230 and steady state (Figure 3).

231 ***Figure 3***

232

233 ***Table 3***

234 (5) Correlation analysis between the change in sequence-specific learning performance with the
235 fMRI signal change in the learning contrast from single dose to steady state within the
236 escitalopram group reveals a significant positive correlation in brain regions including the left
237 premotor cortex (Figure 4; yellow overlay, Supplementary Table 3).

238 (6) Correlational analysis between escitalopram plasma levels and the learning contrast in the
239 escitalopram group shows a significant negative correlation, with increases in escitalopram
240 plasma concentration associated with decreases in the learning contrast in the left supplementary
241 motor area and supramarginal gyrus (Figure 4, Supplementary Table 4).

242 ***Figure 4***

Running Head: fMRI assessment of motor learning and escitalopram

243 **Analysis of mature BDNF levels:**

244 Analysis of mBDNF levels from baseline to steady state in both groups combined does not reveal
245 any significant changes over time ($F(1, 62) = 2.195, p=0.12$), and paired t -tests do not indicate
246 significant changes from baseline to steady state in either the escitalopram ($t = -1.23, p=0.22$) or
247 placebo group ($t = -1.5, p=0.14$), respectively.

Running Head: fMRI assessment of motor learning and escitalopram

248 **Discussion:**

249 In this randomized controlled interventional study, we investigated whether administration of 20
250 mg escitalopram improves motor learning performance and alters functional brain response in the
251 motor network during sequence motor learning. Results show a significant learning effect in
252 sequence-specific motor performance though this rate of improvement does not differ between
253 groups. Additionally, we do not observe any significant group differences at any time point, or in
254 rate of improvement. With fMRI, we find significant escitalopram-induced decreases in the left
255 cortical premotor response during sequence-specific learning comparing single dose and steady
256 levels of escitalopram. Moreover, consideration of behavioral performance as a variable of
257 interest during this phase of learning reveals that these changes in the sequence-specific learning
258 contrast positively correlate with improvement in motor performance. Finally, we observe a
259 negative correlation between escitalopram-plasma levels and the fMRI response during the
260 sequence-specific learning contrast in the left premotor cortex during task-performance,
261 suggesting a parallel development between escitalopram plasma kinetics and the attenuation of
262 cortical motor response to sequence-specific motor learning.

263

264 The lack of an effect of SSRI-administration on motor learning performance differs from
265 previous findings in healthy volunteers³¹⁻³³. These studies, however, were neither powered nor
266 pre-registered to test this as an *a-priori* hypothesis, with six healthy volunteers for five different
267 behavioral tests and one fMRI experiment^{31,32} and nineteen volunteers for six different behavioral
268 assessments³³. Additionally, we administered escitalopram, and chose a task that may be less
269 cognitively demanding due to repetitive isotonic contractions⁵⁵, possibly creating earlier ceiling
270 effects in healthy adults. These previous findings could be specific to paroxetine, require tasks
271 with more spatial and coordination-oriented sensorimotor components, or may only become
272 apparent after several weeks of administration. Nevertheless, given that we administered the

Running Head: fMRI assessment of motor learning and escitalopram

273 SSRI with the highest transporter selectivity⁵⁶, employed a task that reliably measures sequence
274 motor learning⁴⁰, and tested a sample well-powered to detect robust effect sizes, it is unlikely that
275 this discrepancy is due to the choice of SSRI or motor paradigm alone. Furthermore, our
276 exploratory analysis of mature BDNF levels in plasma did not reveal any significant changes
277 associated with improved motor learning performance in either group. While this is consistent
278 with findings of improved motor performance in healthy volunteers to be unrelated to peripheral
279 BDNF levels⁵⁷, evidence supportive of an association between motor skill learning and increased
280 BDNF levels have also been reported⁵⁸. While future studies should assess potential SSRI
281 modulation of motor learning with additional paradigms, our results do not support a beneficial
282 effect of SSRI-administration on motor learning performance in health.

283

284 We do report evidence supportive of our second hypothesis however, with significant decreases
285 in functional responses in left premotor cortex during sequence specific motor learning, relative
286 to placebo (Figure 3). While both increases and decreases in functional brain responses underlie
287 motor learning⁵⁹, this pattern is dependent on differential stages of learning and is defined by
288 multiple parallel processes⁶⁰⁻⁶². Early fast learning is accompanied by rapid improvements in
289 performance, followed by slow learning that characterizes a more consolidatory phase^{63,64}.
290 Patterns of functional responses observed during this phase are also influenced by the type of
291 task, with explicit learning of repetitive and unchanging sequences hypothesized to lead to faster
292 automation of performance^{61,65,66} and a subsequent reduction in cognitive load needed for task
293 completion. Given the predictable repetition of the learning sequence on our task and the timing
294 of our assessments, it is possible that the observed escitalopram-induced decreases in the learning
295 contrast reflect this automation of responses and subsequent consolidation of sequence learning.

Running Head: fMRI assessment of motor learning and escitalopram

296 Such a neural consolidation process in response to 1 week of escitalopram-intake is consistent
297 with a recent conceptual model of SSRI influences on post-stroke recovery⁶⁷. The authors
298 propose that acute SSRI exposure changes the excitatory and inhibitory balance with increases in
299 excitatory signaling, allowing for the remodeling of cortical pathways⁶⁷. Subsequent SSRI
300 exposure leads to a reset in homeostasis with a heightening of γ -aminobutyric acid (GABA)
301 tone⁶⁷, allowing for remodeled pathways to become engrained as task performance continues.
302 Further support for this interpretation stems from studies identifying an inverse relationship
303 between cortical GABA concentrations and functional brain responses^{68,69} and SSRI
304 administration has been shown to increase cortical GABA levels in rodents⁷⁰ and healthy
305 volunteers⁷¹. Finally, the observation that the escitalopram-induced decrease in the learning
306 contrast is negatively associated with escitalopram kinetics occurs in a timeframe consistent with
307 that typically required for 5-HT_{1A} autoreceptor desensitization⁷², which could also modulate
308 effective enhancement of cortical GABAergic tone⁷³. In summary, it is possible that this
309 escitalopram-induced decrease in premotor response in the learning contrast reflects more
310 effective neural task processing, relative to placebo, in a region central to temporally and
311 visually-oriented motor learning and planning⁷⁴⁻⁷⁷. This interpretation is consistent with the
312 hypothesis of an SSRI-induced window of experience-dependent plasticity as an attenuator of
313 neural efficiency during performance^{25,26}.

314

315 An alternative explanation of this finding is a habituation effect of neural responses during
316 repetitive sequence-specific motor learning that may be emphasized by escitalopram
317 administration. While we report a significant three-way interaction for brain, task, and group
318 (Figure 4), this effect is limited to the comparison between a single dose and steady state and in
319 the escitalopram group only, despite the observation that both groups successfully improve
320 performance over time. It is possible that the neural responses during task performance in the

Running Head: fMRI assessment of motor learning and escitalopram

321 placebo group reflects a simpler order effect, whereby neural responses adapt incrementally,
322 rather than via an adaptive plasticity mechanism. Integration of more direct measures of cortical
323 excitation and inhibition can allow for more fine-grained investigations into acute and subacute
324 SSRI-effects.

325

326 Nevertheless, there are some limitations to consider when interpreting these results. We
327 acknowledge that the initial strong learning effect may have masked more subtle modulation of
328 performance with escitalopram at a later training session. Though a known limitation of this task,
329 we chose the SPFT for this well-established and reliable learning effect. While performance
330 reaches a ceiling during the fourth and fifth sessions, as described previously⁴⁰, we still observe a
331 considerable change in performance after the administration of the single dose and subsequent
332 training sessions, thus maintaining the falsifiability of our primary hypothesis. Second, our results
333 may not generalize to males or older adults as our sub-sample consists only of females with
334 standardized downregulation of ovarian hormones. This was a deliberate *a-priori* restriction to
335 eliminate confounds such as sex-differences³³ and fluctuating endogenous hormones⁷⁸ on
336 environmental learning and escitalopram responsivity. Third, other studies have gradually
337 increased escitalopram doses for pharmaco-fMRI protocols in healthy participants⁷⁹ to minimize
338 adverse effects. We chose a fixed dose of 20 mg to reliably block 80 % of 5-HTT³⁷, an approach
339 previously well tolerated²⁸. While four participants discontinued protocol because of adverse
340 effects in the escitalopram group, this was also the case for two placebo participants, and there
341 was no group difference in self-reported side effects at steady state. Finally, fMRI provides an
342 indirect measure of neural activity, which is susceptible to non-neural changes such as vascular
343 uncoupling. Given the functional specificity of the premotor cortex, it is unlikely that these
344 findings are solely driven by changes in global blood flow. We cannot, however, identify
345 underlying molecular mechanisms, which require quantitative measures such as MR-

Running Head: fMRI assessment of motor learning and escitalopram

346 spectroscopy measures of GABA and glutamate or [¹¹C]UCB-J positron emission tomography, a
347 recently developed technique for *in vivo* imaging of synaptic plasticity^{80,81}.

348

349 In conclusion, this is the first study to investigate the effect of steady escitalopram administration
350 on motor learning in an established sequential motor learning paradigm and the associated brain
351 response in a sufficiently powered sample. In this pre-registered, randomized, controlled,
352 interventional study, we do not find evidence in support of improved performance in response to
353 1 week of escitalopram-intake during sequence-specific motor training. A major difference we
354 observe between groups is a decrease in premotor cortical responses during sequence-specific
355 learning performance contrasting single dose and steady drug state. Considering previous
356 findings on sequential motor learning and associated neural correlates in the motor network, less
357 premotor response during similar performance may suggest more effective neural processing and
358 greater consolidation of performance⁶⁴. By combining escitalopram administration and sequence-
359 specific motor training for one week, we provide the first empirically tested framework for
360 assessing SSRI-effects on human adaptive motor plasticity in health. Our paradigm and findings
361 may help disentangle the seemingly contradictory results between preclinical models and recent
362 clinical trials and represent an important milestone towards understanding the role of SSRIs in
363 human motor learning.

Running Head: fMRI assessment of motor learning and escitalopram

Acknowledgements:

We thank Heike Schmidt-Duderstedt and Kerstin Flake for assisting with preparation of the figures and Dr. Kristin Ihle for her assistance with medical supervision of all participants during the experiments, and PD Dr. Veronica Witte for statistical discussion.

Running Head: fMRI assessment of motor learning and escitalopram

Authors' Contributions Statement:

ENM: Conceptualization, Investigation, Methodology, Formal analysis, Writing - original draft, Writing - review & editing, Visualization, Funding acquisition

KM: Conceptualization, Methodology, Formal analysis, Writing - review & editing, Visualization

NB: Conceptualization, Methodology

MB: Formal analysis, Writing - review & editing

FAP: Formal analysis, Writing - review & editing

AP: Methodology

CJ: Methodology, Formal analysis

US: Conceptualization, Methodology

GZ: Conceptualization, Methodology

RR: Formal analysis, Writing - review & editing

BS: Writing - review & editing

VVN: Writing - review & editing

HEM: Methodology, Writing - review & editing

AV: Writing - review & editing

JS: : Conceptualization, Investigation, Methodology, Writing - review & editing, Visualization, Funding acquisition

Running Head: fMRI assessment of motor learning and escitalopram

Competing Interests:

The authors declare that no competing interests exist.

Funding:

This research was supported by the FAZIT Foundation to ENM and The Branco Weiss Fellowship – Society in Science to JS and the Max Planck Society.

Running Head: fMRI assessment of motor learning and escitalopram

References:

1. Diedrichsen, J., Kornysheva, K. (2015). Motor skill learning between selection and execution. *Trends Cogn Sci.* 19(4):227-33. doi: 10.1016/j.tics.2015.02.003.
2. Molina-Luna K., Pektanovic, A., Röhrich, S., Hertler, B., Schubring-Giese, M., Rioult-Pedotti, MS., Luft, A.R. (2009). Dopamine in motor cortex is necessary for skill learning and synaptic plasticity. *PLoS One.* 17;4(9):e7082. doi:10.1371/journal.pone.0007082.
3. Rioult-Pedotti, MS., Pektanovic, A., Atiemo, CO., Marshall, J., Luft, AR. (2015). Dopamine Promotes Motor Cortex Plasticity and Motor Skill Learning via PLC Activation. *PLoS One.* 10(5):e0124986. doi: 10.1371/journal.pone.0124986.
4. Vitrac, C., Benoit-Marand, M. (2017) Monoaminergic Modulation of Motor Cortex Function. *Front. Neural Circuits* 11:72. doi: 10.3389/fncir.2017.00072.
5. Flöel, A., Breitenstein, C., Hummel, F., Celnik, P., Gingert, C., Sawaki, L., Knecht, S., Cohen, LG. (2005). Dopaminergic influences on formation of a motor memory. *Ann Neurol.* 58(1):121-30. doi:10.1002/ana.20536.
6. Flöel, A., Garraux, G., Xu, B., Breitenstein, C., Knecht, S., Herscovitch, P., Cohen, LG. (2008). Levodopa increases memory encoding and dopamine release in the striatum in the elderly. *Neurobiol Aging.* 29(2):267-79. doi:10.1016/j.neurobiolaging.2006.10.009
7. Magrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., Zanette, G., Tamburin, S. (2016). Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. *Parkinsons Dis.* doi:10.1155/2016/9832839
8. Maya Vetencourt, JF., Sale, A., Viegi, A., Baroncelli, L., De Pasquale, R., O'Leary, OF., Castrén, E., Maffei, L. (2008). The antidepressant fluoxetine restores plasticity in the adult visual cortex. *Science,* 320(5874), 385-388. doi:10.1126/science.1150516.
9. Chollet, F., Tardy, J., Albucher, JF., Thalamas, C., Berard, E., Lamy, C., Bejot, Y., Deltour, S., Jaillard, A., Niclot, P., Guillon, B., Moulin, T., Marque, P., Pariente J, Arnaud, C. Loubinoux, I. (2011). Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. *Lancet Neurol,* 10(2), 123-130. doi:10.1016/S1474-4422(10)70314-8.
10. Cipriani, A., Furukawa, TA., Salanti, G., Chaimani, A., Atkinson, LZ., Ogawa, Y., Leucht, S., Ruhe, HG., Turner, EH., Higgins, JPT., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, JPA., Geddes, JR. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet.* 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7.
11. Hackett, ML., Anderson, CS., House, A., Halteh, C. (2006). Interventions for preventing depression after stroke. *Cochrane Database Syst Rev.* 16;(3):CD003689. doi: 10.1002/14651858.CD003689.pub3.

Running Head: fMRI assessment of motor learning and escitalopram

12. Acler, M., Robol, E., Fiaschi, A., Manganotti, P. (2009). A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. *Journal of Neurology* 256(7):1152-8. doi: 10.1007/s00415-009-5093-7.
13. Mead, GE., Hsieh, CF., Hackett, M. (2013). Selective serotonin reuptake inhibitors for stroke recovery. *JAMA*. 310(10):1066-7. doi: 10.1001/jama.2013.107828.
14. Lim, CM., Kim, SW., Park, JY., Kim, C., Yoon, SH., Lee, JK. (2009). Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. *J Neurosci Res*. 87(4):1037-45. doi: 10.1002/jnr.21899.
15. Tynan, RJ., Weidenhofer, J., Hinwood, M., Cairns, MJ., Day, TA., Walker, FR. (2012). A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. *Brain Behav Immun*. 26(3):469-79. doi: 10.1016/j.bbi.2011.12.011.
16. Schmidt, HD., Duman, RS. (2007). The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. *Behav Pharmacol*. 18(5-6):391-418. doi: 10.1097/FBP.0b013e3282ee2aa8
17. Malberg, JE., Eisch, AJ., Nestler, EJ., Duman, RS. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. *J Neurosci*. 15;20(24):9104-10. doi: <https://doi.org/10.1523/JNEUROSCI.20-24-09104.2000>.
18. Lyons, L., ElBeltagy, M., Umka, J., Markwick, R., Startin, C., Bennett, G., Wigmore, P. (2011). Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy. *Psychopharmacology (Berl)*. 215(1):105-15. doi: 10.1007/s00213-010-2122-2.
19. Cooke, JD., Grover, LM., Spangler, PR. (2009). Venlafaxine treatment stimulates expression of brain-derived neurotrophic factor protein in frontal cortex and inhibits long-term potentiation in hippocampus. *Neuroscience*. 162(4):1411-9. doi: 10.1016/j.neuroscience.2009.05.037.
20. Pälvimäki, EP., Laakso, A., Kuoppamäki, M., Syvälahti, E., Hietala, J. (1994). Up-regulation of β 1-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. *Psychopharmacology*. 115: 543. <https://doi.org/10.1007/BF02245579>
21. Yan, Z. (2002). Regulation of GABAergic inhibition by serotonin signalling in prefrontal cortex. *Molecular Neurobiology* 26(2-3) 203-216. doi: 10.1385/MN:26:2-3:203
22. Choi, HC., Kim, YI., Song, HK., Kim, JE., Kim, DS., Kang, TC. (2010). Effects of selective serotonin reuptake inhibitors on GABAergic inhibition in the hippocampus of normal and pilocarpine induced epileptic rats. *Brain Res*. 1357:131-41. doi: 10.1016/j.brainres.2010.08.010.

Running Head: fMRI assessment of motor learning and escitalopram

23. Mlinar, B., Stocca, G., Corradetti, R. (2015). Endogenous serotonin facilitates hippocampal long-term potentiation at CA3/CA1 synapses. *J Neural Transm(Vienna)*. 122(2):177-85. doi: 10.1007/s00702-014-1246-7.
24. Batsikadze, G., Paulus, W., Kuo, MF., Nitsche, MA. (2013). Effect of serotonin on paired associative stimulation-induced plasticity in the human motor cortex. *Neuropsychopharmacology*, 38(11), 2260-2267. doi:10.1038/npp.2013.127.
25. Castrén, E. (2005). Is mood chemistry? *Nat Rev Neurosci*, 6(3), 241-246. doi:10.1038/nrn1629
26. Castrén, E. (2013). Neuronal network plasticity and recovery from depression. *JAMA Psychiatry*, 70(9), 983-989. doi:10.1001/jamapsychiatry.2013.1
27. Siepmann, T., Penzlin, A.I., Kepplinger, J., Illigens, BM., Weidner, K., Reichmann, H., Barlind, K. (2015). Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. *Brain Behav*. 23;5(10): e00373. doi: 10.1002/brb3.373.
28. Schaefer, A., Burmann, I., Regenthal, R., Arélin, K., Barth, C., Pampel, A., Villringer, A., Margulies, DS., Sacher, J. (2014). Serotonergic modulation of intrinsic functional connectivity. *Current Biology*, 24(19), 2314-2318. doi: 10.1016/j.cub.2014.08.024.
29. Knott, VJ., Howson, AL., Perugini, M., Ravindran, AV., & Young, SN. (1999). The Effect of Acute Tryptophan Depletion and Fenfluramine on Quantitative EEG and Mood in Healthy Male Subjects. *Biological Psychiatry*; (46) 229–238.
30. Loubinoux, I., Boulanouar, K., Ranjeva, JP., Carel, C., Berry, I., Rascol, O., Celsis, P., Chollet, F. (1999). Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. *J Cereb Blood Flow Metab*. 19(12):1365-75. doi: 10.1097/00004647-199912000-00010
31. Loubinoux, I., Pariente, J., Boulanouar, K., Carel, C., Manelfe, C., Rascol, O., Celsis, P., Chollet, F. (2002a). A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. *Neuroimage*, 15(1), 26-36. doi:10.1006/nimg.2001.0957.
32. Loubinoux, I., Pariente, J., Rascol, O., Celsis, P., Chollet, F. (2002b). Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects. *Neuropsychologia*. 40(11):1815-21.
33. Loubinoux, I., Tombari, D., Pariente, J., Gerdelat-Mas, A., Franceries, X., Cassol, E., Rascol, O., Pastor, J., Chollet, F. (2005). Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. *Neuroimage*. 27(2):299-313. doi:10.1016/j.neuroimage.2004.12.023
34. Kraglund, KL., Mortensen, JK., Damsbo, AG., Modrau, B., Simonsen, SA., Iversen, HK., Madsen, M., Grove, EL., Johnsen, SP., Andersen, G. (2018). Neuroregeneration and

Running Head: fMRI assessment of motor learning and escitalopram

- Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS). *Stroke*. 49(11):2568-2576. doi:10.1161/STROKEAHA.117.020067.
35. FOCUS Trial Collaboration. (2019). Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. *Lancet*. 393(10168):265-274. doi: 10.1016/S0140-6736(18)32823-X.
36. van der Worp, BH. (2019). Fluoxetine and recovery after stroke. *Lancet*. 393(10168):206-207. doi: 10.1016/S0140-6736(18)32983-0.
37. Klein, N., Sacher, J., Geiss-Granadia, T., Attarbaschi, T., Mossaheb, N., Lanzenberger, R., Pötzi, C., Holik, A., Spindelegger, C., Asenbaum, S., Dudczak, R., Tauscher, J., Kasper S. (2006). In vivo imaging of serotonin transporter occupancy by means of SPECT and [¹²³I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. *Psychopharmacology (Berl)*. 188(3):263-72. doi:10.1007/s00213-006-0486-0.
38. Kasper, S., Spadone C., Verpillat P., Angst J. (2006). Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. *Int Clin Psychopharmacol*. 21(2):105-10.
39. Sanchez, C., Reines, EH., Montgomery, SA. (2014). A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? *Int Clin Psychopharmacol*. 29(4):185-96. doi: 10.1097/YIC.0000000000000023.
40. Gryga, M., Taubert, M., Dukart, J., Vollmann, H., Conde, V., Sehm, B., Villringer, A., Ragert, P. (2012). Bidirectional gray matter changes after complex motor skill learning. *Front Syst Neurosci*, 6:37. doi:10.3389/fnsys.2012.00037
41. Pasqualetti G., Gori G., Blandizzi C., Del Tacca, M. (2010). Healthy volunteers and early phases of clinical experimentation. *Eur J Clin Pharmacol*.;66(7):647-53. doi: 10.1007/s00228-010-0827-0.
42. Karakunnel, JJ., Bui, N., Palaniappan, L., Schmidt, KT., Mahaffey, KW., Morrison, B., Figg, WD., Kummar, S. (2018). Reviewing the role of healthy volunteer studies in drug development. *J Transl Med*. 4;16(1):336. doi: 10.1186/s12967-018-1710-5.
43. van Dyck, CH., Malison, RT., Seibyl, JP., Laruelle, M., Klumpp, H., Zoghbi, SS., Baldwin, RM., Innis, RB. (2000) Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT. *Neurobiol Aging*. 21(4):497-501. doi: 10.1016/s0197-4580(00)00152-4.
44. Hampson, E. & Kimura D. (1988). Reciprocal effects of hormonal fluctuations on human motor and perceptual-spatial skills. *Behav Neurosci*. 102(3):456-9. doi:10.1037//0735-7044.102.3.456
45. Barth, C., Villringer, A., Sacher, J. (2015). Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. *Front Neurosci*. 9:37. doi: 10.3389/fnins.2015.00037.

Running Head: fMRI assessment of motor learning and escitalopram

46. LeGates, T., Kvarita, MD., Thompson, SM. (2019). Sex differences in antidepressant efficacy. *Neuropsychopharmacology*;44(1):140-154. doi: 10.1038/s41386-018-0156-z.
47. Uher, R., Farmer, A., Henigsberg, N., Rietschel, M., Mors, O., Maier, W., Kozel, D., Hauser, J., Souery, D., Placentino, A., Strohmaier, J., Perroud, N., Zobel, A., Rajewska-Rager, A., Dernovsek, MZ., Larsen, E.R., Kalember, P., Giovannini, C., Barreto, M., McGuffin, P., Aitchison, KJ. (2009). Adverse reactions to antidepressants. *Br J Psychiatry*. 195(3):202-10. doi: 10.1192/bjp.bp.108.061960.
48. Rao, N. (2007). The Clinical Pharmacokinetics of Escitalopram. *Clinical Pharmacokinetics* 46(4):281-90. DOI: 10.2165/00003088-200746040-00002.
49. R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
50. Faul, F., Erdfelder, E., Lang, AG, Buchner A. (2007). G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods*. 39(2):175-91. doi:10.3758/bf03193146.
51. Iglewicz, B., Banerjee, S. (2001). A simple univariate outlier identification procedure. Proceedings of the Annual Meeting of the American Statistical Association.
52. Mugler, JP., 3rd, Brookeman, J.R. (1990). Three-dimensional magnetization-prepared rapid gradient-echo imaging (3D MP RAGE). *Magn Reson Med*;15(1):152-157. doi: 10.1002/mrm.1910150117.
53. Streitbürger, DP., Pampel, A., Krueger, G., Lepsien, J., Schroeter, ML., Mueller, K., Möller, HE. (2014). Impact of image acquisition on voxel-based-morphometry investigations of age-related structural brain changes. *Neuroimage*. 15; 87:170-82. doi:10.1016/j.neuroimage.2013.10.051.
54. Holiga, Š., Mueller, K., Möller, HE., Sieger, T., Schroeter, ML., Vymazal, J. (2013). Motor matters: tackling heterogeneity of Parkinson's disease in functional MRI studies. *PLoS One*. 2013;8:e56133. doi.org/10.1371/journal.pone.0056133.
55. Hardwick, RM., Rottschy, C., Miall, RC., Eickhoff, SB. (2013). A quantitative meta-analysis and review of motor learning in the human brain. *Neuroimage*. 15; 67:283-97. doi: 10.1016/j.neuroimage.2012.11.020.
56. Owens, MJ., Knight, DL., Nemeroff, CB. (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. *Biol Psychiatry*. 50(5):345-50. doi: 10.1016/s0006-3223(01)01145-3
57. Baird, JF., Gaughan, ME., Saffer, HM., Sarzynski, MA., Herter, TM., Fritz, SL., den Ouden, DB., Stewart, J.C. (2018). The effect of energy-matched exercise intensity on brain-derived neurotrophic factor and motor learning. *Neurobiol Learn Mem*. 156:33-44. doi: 10.1016/j.nlm.2018.10.008.
58. Grégoire, CA., Berryman, N., St-Onge, F., Vu, TTM., Bosquet, L., Arbour, N., Bherer, L. (2019). Gross Motor Skills Training Leads to Increased Brain-Derived Neurotrophic

Running Head: fMRI assessment of motor learning and escitalopram

- Factor Levels in Healthy Older Adults: A Pilot Study. *Front Physiol.* 10: 410. doi:10.3389/fphys.2019.00410.
59. Wymbs, FN., & Grafton, ST. (2014). The Human Motor System Supports Sequence-Specific Representations over Multiple Training-Dependent Timescales. *Cerebral Cortex*, 25(11) 4213–4225, doi: <https://doi.org/10.1093/cercor/bhu144>
60. Penhune, VB., Steele, CJ. (2012). Parallel contributions of cerebellar, striatal and M1 mechanisms to motor sequence learning. *Behav Brain Res.* 15;226(2):579-91. doi: 10.1016/j.bbr.2011.09.044.
61. Toni, I., Krams, M., Turner, R., Passingham, RE. (1998). The time course of changes during motor sequence learning: a whole-brain fMRI study. *Neuroimage.* 8(1):50-61. doi:<https://doi.org/10.1006/nimg.1998.0349>
62. Luft, AR., Buitrago, MM. (2005). Stages of motor skill learning. *Mol Neurobiol* 32(3):205-16. doi:10.1385/MN:32:3:205.
63. Karni, A., Meyer, G., Rey-Hipolito, C., Jezzard, P., Adams, MM., Turner. R., Ungerleider, LG. (1998). The acquisition of skilled motor performance: fast and slow experience-driven changes in primary motor cortex. *PNAS*;3;95(3):861-8. doi: 10.1073/pnas.95.3.861.
64. Hotermans, C., Peigneux, P., Maertens de Noordhout, A., Moonen, G., Maquet, P. (2006). Early boost and slow consolidation in motor skill learning. *Learn Mem.*;13(5):580-3. doi:10.1101/lm.239406
65. Poldrack, RA., Sabb, FW., Foerde, K., Tom, SM., Asarnow, RF., Bookheimer, SY., Knowlton, BJ. (2005). The neural correlates of motor skill automaticity. *J Neurosci.* 25(22):5356-64. doi: <https://doi.org/10.1523/JNEUROSCI.3880-04.2005>
66. Yang, J. (2015). The influence of motor expertise on the brain activity of motor task performance: A meta-analysis of functional magnetic resonance imaging studies. *Cogn Affect Behav Neurosci.* 15(2):381-94. doi: 10.3758/s13415-014-0329-0.
67. Schneider CL, Majewska AK, Busza A, Williams ZR, Mahon BZ, Sahin B. (2019). Selective serotonin reuptake inhibitors for functional recovery after stroke: Similarities with the critical period and the role of experience-dependent plasticity. *J Neurol.* 1-7. doi: 10.1007/s00415-019-09480-0
68. Stagg, CJ., Bachtiar, V., Johansen-Berg, H. (2011). The role of GABA in human motor learning. *Curr Biol.* 21(6):480-4. doi: 10.1016/j.cub.2011.01.069.
69. Stagg, CJ., Bachtiar, V., Amadi, U., Gudberg, CA., Ilie, AS., Sampaio-Baptista, C., O'Shea, J., Woolrich, M., Smith, SM., Filippini, N., Near, J., Johansen-Berg H. (2014). Local GABA concentration is related to network-level resting functional connectivity. *Elife.* 25;3:e01465. doi: 10.7554/eLife.01465.
70. Chen, Z., Silva, AC., Yang, J., Shen, J. (2005). Elevated endogenous GABA level correlates with decreased fMRI signals in the rat brain during acute inhibition of GABA transaminase. *J Neurosci Res.* 79(3):383-91.

Running Head: fMRI assessment of motor learning and escitalopram

71. Bhagwagar, Z., Wylezinska, M., Taylor, M., Jezzard, P., Matthews, PM., Cowen, PJ. (2004). Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. *Am J Psychiatry*. 161(2):368-70. doi: 10.1176/appi.ajp.161.2.368
72. El Mansari, M., Sánchez, C., Chouvet, G., Renaud, B., Haddjeri, N. (2005). Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. *Neuropsychopharmacology*. 30(7):1269-77. doi:10.1038/sj.npp.1300686
73. Lladó-Pelfort, L., Santana, N., Ghisi, V., Artigas, F., Celada, P. (2012). 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons. *Cereb Cortex*. 22(7):1487-97. doi: 10.1093/cercor/bhr220.
74. Karim, HT., Huppert, TJ., Erickson, KI., Wollam, ME., Sparto, PJ., Sejdić, E., Van Swearingen, JM. (2017). Motor sequence learning-induced neural efficiency in functional brain connectivity. *Behav Brain Res*. 15;319:87-95. doi: 10.1016/j.bbr.2016.11.021.
75. Mushiake, H., Inase, M., Tanji, J. (1991). Neuronal activity in the primate premotor, supplementary, and precentral motor cortex during visually guided and internally determined sequential movements. *J Neurophysiol*;66(3):705-18.
76. Halsband, U., Ito, N., Tanji, J., Freund, HJ. (1993). The role of premotor cortex and the supplementary motor area in the temporal control of movement in man. *Brain*;116 (Pt 1):243-66. doi:10.1093/brain/116.1.243.
77. Kalaska, JF., Crammond, DJ. (1995). Deciding not to GO: neuronal correlates of response selection in a GO/NOGO task in primate premotor and parietal cortex. *Cereb Cortex*.;5(5):410-28. doi:10.1093/cercor/5.5.410.
78. Bianchini, F., Verde, P., Colangeli, S., Boccia, M., Strollo, F., Guariglia, C., Bizzarro, G., Piccardi, L. (2018). Effects of oral contraceptives and natural menstrual cycling on environmental learning. *BMC Womens Health*. 18(1):179. doi: 10.1186/s12905-018-0671- 4.
79. Henry, ME., Lauriat, TL., Lowen, SB., Churchill, JH., Hodgkinson, CA., Goldman, D., Renshaw, PF. (2013). Effects of citalopram and escitalopram on fMRI response to affective stimuli in healthy volunteers selected by serotonin transporter genotype. *Psychiatry Res*. 213(3): 217–224. doi:10.1016/j.psychres.2013.05.008.
80. Finnema, SJ., Nabulsi, NB., Eid, T., Detyniecki, K., Lin, SF., Chen, MK., Dhaher, R., Matuskey, D., Baum, E., Holden, D., Spencer, DD., Mercier, J., Hannestad, J. Huang, Y., Carson, RE. Imaging synaptic density in the living human brain. *Sci Transl Med*. 8(348):348ra96. doi: 10.1126/scitranslmed.aaf6667.
81. Chen, MK., Mecca, AP., Naganawa, M., Finnema, SJ., Toyonaga, T., Lin, SF., Najafzadeh, S., Ropchan, J., Lu, Y., McDonald, JW., Michalak, HR., Nabulsi, NB., Arnsten, AFT., Huang, Y., Carson, RE, van Dyck, CH. (2018). Assessing Synaptic

Running Head: fMRI assessment of motor learning and escitalopram

Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron
Emission Tomographic Imaging. *JAMA Neurol.* 75(10):1215-1224. doi:
10.1001/jamaneurol.2018.1836.

Running Head: fMRI assessment of motor learning and escitalopram

Figures & Figure Legends:




Figure 1. Study design and task: Following baseline, escitalopram or placebo administration took place for 7 consecutive days. Post baseline, motor training took place at single dose (first day), days 5 and 6, and at steady state (day 7). Motor training on days 5 and 6 was completed outside the scanner. fMRI data were acquired at baseline, single dose, and steady state. Task = Sequential Pinch Force Task, fMRI = Functional Magnetic Resonance Imaging, Force = the yellow bar controlled by the participants, the rise and fall of which was required to match the rise and fall of the blue (reference bar, i.e., the bar controlled by a computer).

Running Head: fMRI assessment of motor learning and escitalopram




Figure 2. Sequential motor learning: **Left:** Significant improvements in lag scores over 5 days of sequential motor training across both escitalopram and placebo. However, despite a significant learning effect, we observed no significant group differences in performance, nor did we observe an interaction effect. **Right:** Comparison of the rate of change between baseline and steady state yield no significant group differences. Bold fonts indicate training completed in the scanner.

Running Head: fMRI assessment of motor learning and escitalopram




Figure 3. Escitalopram-induced decreases in cortical motor responses during sequential motor learning: Orthogonal brain slices showing group dependent changes in the learning contrast over time. Mean functional group response (red) of the escitalopram group (top) and placebo (bottom) at each baseline, single dose, and steady state measurements, as computed by a series of one-sample *t*-tests in SPM12. **Single Dose>Steady State:** Brain regions in the escitalopram group with significant decreases in the learning contrast (blue) between single dose and steady state (top row) show decreases in bilateral premotor and temporal-parietal regions (Table 3). Comparisons between single dose with steady state in the placebo group do not yield any significant changes across time (bottom). **Interaction:** Comparisons of groups over time reveal decreases in the learning contrast signal in the left premotor cortex of the escitalopram group that are not observed in placebo (violet). Consideration of behavioral performance as a variable of interest shows brain regions where changes in the learning contrast positively correlate with improvement in motor performance, also with a peak in the left premotor cortex (overlaid in yellow). All results are shown for sequence-specific learning with $p < 0.05$ family-wise error (FWE) correction at a cluster forming threshold of $p < 0.001$. All orthogonal planes presented are the same. β = beta value at global maximum coordinate.

Running Head: fMRI assessment of motor learning and escitalopram




Figure 4: Correlations between escitalopram plasma levels and cortical premotor response during sequence-specific learning from single dose to steady state: (A) Escitalopram plasma concentrations negatively correlate with changes in the learning contrast in bilateral cortical motor regions, including the premotor cortex (premotor cortex from significant 2×2 interaction overlaid in yellow), with a peak in the left supramarginal gyrus. (B) Betas containing parameter estimates for error from the left premotor cortex plotted against escitalopram plasma levels at single dose and steady state, respectively. Results refer to the sequence-specific learning contrast and are shown with $p < 0.05$ family-wise error (FWE) correction at a cluster forming threshold of $p < 0.001$. Escit. = escitalopram, ng/ml = nanograms/milliliters. β = beta value at premotor MNI coordinates.

Running Head: fMRI assessment of motor learning and escitalopram

Tables:

Table 1. Demographic overview: Group demographic overview and mean single dose and steady state escitalopram plasma concentrations. Group values refer to mean \pm standard deviation. Demographic values rounded to the nearest whole number. Escit. = escitalopram, ASEC = antidepressant side effect checklist-score, kg/m² = kilogram force per square meter, u/l = units per liter, ng/ml = nanograms/milliliters.

	Escitalopram (n=31)	Placebo (n=33)	<i>t</i> -value	<i>p</i> -value
Age (years)	24 \pm 3	23 \pm 4	-0.3	0.74
BMI (kg/m ²)	22 \pm 2	21 \pm 2	-1.3	0.19
Lutropin (u/l)	2 \pm 2	1 \pm 2	-1.2	0.20
Follitropin (u/l)	3 \pm 3	2 \pm 3	-1.3	0.19
ASEC single dose	3 \pm 3	1 \pm 1	3.9	\leq 0.001
ASEC steady state	1 \pm 2	1 \pm 1	-0.7	0.48
Escit. single dose (ng/ml)	20 \pm 5	-	-	-
Escit. steady state (ng/ml)	46 \pm 11	-	-	-

Running Head: fMRI assessment of motor learning and escitalopram

Table 2. Comparisons of nested linear mixed effects models and post-hoc testing for sequence-specific lag scores: Model comparisons for computing the omnibus tests for *group* and *time* as well as their interaction effect for both outcome measures. χ^2 and respective *p*-values were computed from LRT between nested models with results of independent samples *t*-tests and corresponding Bayes Factors on mean single dose, steady state, and absolute rate of improvement scores (deltas). BF_{01} = Bayes Factor indicating the likelihood of the alternative hypothesis compared to the null hypothesis. $M \pm SD$ = means \pm standard deviation, LRT = likelihood ratio test, df = degrees of freedom, χ^2 = Chi-square. *Significant improvement in model fit.

Mixed Effects Modelling	Fixed Effects	Random effects	LRT		Marginal R^2
			χ^2 (df)	<i>p</i> -value	
Intercept	-	Subject	-	-	0
Time	time	Subject	3301.3 (24)	$\leq 0.001^*$	0.2917
Group	group+time	Subject	0.0181 (1)	0.8931	0.2918
Interaction	group*time	Subject	25.722 (24)	0.3674	0.2934
Post-hoc Testing	Escitalopram $M \pm SD$	Placebo $M \pm SD$	<i>t</i> -value (df)	<i>p</i> -value	Cohen's d/ BF_{01}
Single dose	99.8 \pm 57.9	95.1 \pm 67.8	-0.3 (62)	0.76	-0.07/0.26
Steady state	58.1 \pm 36.1	63.8 \pm 44.1	0.56 (62)	0.57	0.14/0.29
Delta scores	-107.1 \pm 56.6	-96.7 \pm 59.2	0.71 (62)	0.47	0.18/0.31

Running Head: fMRI assessment of motor learning and escitalopram

Table 3. Escitalopram-induced motor network changes in the learning contrast during sequence motor learning: Results of a paired comparison of single dose and steady state within the escitalopram group and subsequent interaction comparisons with placebo. All results obtained with a 2x2 flexible factorial design. T=t-values, Z=z-values, MNI(x,y,z)=MNI peak coordinates, Escit. = escitalopram group.

Brain Region	<i>p</i> (FWE-corr)	Cluster Extent	T	Z	MNI (x,y,z)
<i>Escit. Paired</i>					
Left Premotor Cortex	<0.001	913	6.33	5.50	-18, 11, 59
			6.25	5.44	-21, 11, 50
			6.17	5.39	-27, 8, 59
Right Premotor Cortex	<0.001	233	6.15	5.38	30, -4, 41
			5.10	4.62	24, -4, 65
			4.28	3.97	30, 2, 62
Left Superior Parietal Lobule	<0.001	260	5.82	5.14	-39, -46, 53
			5.33	4.79	-33, -43, 32
			5.13	4.64	-36, -46, 41
Left Middle Temporal Gyrus	0.025	97	4.97	4.52	-48, -58, -4
			3.33	3.17	-39, -67, 8
Left Superior Frontal Gyrus	<0.001	295	4.87	4.44	-18, 35, 38
			4.53	4.17	-18, 44, 20
			4.31	4.00	-15, 56, 26
Right Superior Parietal Lobule	<0.001	257	4.74	4.34	12, -61, 62
			4.23	3.93	18, -61, 50
			4.06	3.79	33, -40, 59
Left Postcentral Gyrus	<0.001	215	4.70	4.30	-9, -46, 74
			4.67	4.28	-12, 52, 65
			3.63	3.44	-15, -70, 50
Right Middle Temporal Gyrus	0.002	172	4.67	4.29	42, -58, 11
			3.77	3.55	33, -58, 23
			3.68	3.47	27, -76, 11
<i>Interaction</i>					
Left Premotor Cortex	0.044	82	4.36	4.04	-21, 11, 50
			4.17	3.88	-15, 8, 59
			4.10	3.82	-18, -4, 59
<i>Interaction (Sensitivity)</i>					
Left Premotor Cortex	0.017	111	4.68	4.29	-21, 11, 50
			4.26	3.95	-15, 8, 59
			4.07	3.80	-27, 5, 56